Farag Ibrahim Eltaib

Farag Ibrahim Eltaib

Biotechnology Research Center, Tripoli - Tajura / Libya
Medical and Health Sciences / Biochemistry
AD Scientific Index ID: 4512320
Biotechnology Research Center
person_outline Farag Ibrahim Eltaib's MOST POPULAR ARTICLES
1-) Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-κB and sensitizes Hodgkin\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'s lymphoma cells for natural killer cell–mediated cytotoxicityB Böll, F Eltaib, KS Reiners, B von Tresckow, S Tawadros, VR Simhadri, ...Clinical Cancer Research 15 (16), 5108-5116, 2009622009
2-) Partial purification and characterization of chitin deacetylase from Mucor rouxiiFI Eltaib11999
3-) HSP90 as a novel target therapy for the treatment of Hodgkin’s LymphomaFI EltaibKöln, Univ., Diss., 2010, 20102010
4-) Novel HSP90 inhibitor CNF2024 selectively kills Hodgkin lymphoma cells by depleting NFKB and inhibits HL tumor growth in vivoB Boell, F Eltaib, K Lundgren, K Reiners, S Tawadros, B von Tresckow, ...HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 92, 70-70, 20072007
5-) Aus dem Zentrum für Innere Medizin der Universität zu Köln Klinik I für Innere Medizin Direktor: Universitätsprofessor Dr. med. M. HallekFI Eltaib